iPierian is a biotechnology company targeting secreted Tau for treatment of Alzheimer's disease and other Tauopathies. The company's lead drug candidate (IPN007) is a monoclonal antibody targeting a novel form of secreted Tau that is differentially regulated in Alzheimer's disease patients, designed to slow the spread of Tau throughout the brain and therefore inhibit the associated disease progression.